1018 A. Siddiqui et al. autosomal recessive juvenile parkinsonism. Nature 1998; 392:605–608. [7] Kroemer G, Marino G, Levine B. Autophagy and the inte- grated stress response. Mol.Cell 2010;40:280–293. [8] Kumar MJ, Andersen JK. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol Neurobiol 2004;30:77–89. [9] Kumar MJ, Nicholls DG, Andersen JK. Oxidative alpha- ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare res- piratory capacity: implications for Parkinson’s disease. J Biol Chem 2003;278:46432–46439. [10] Langston JW, Ballard PA Jr. Parkinson’s disease in a chem- ist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyri- dine. N Engl J Med 1983;309:310. [11] Lavoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG. The effects of oxidative stress on parkin and other E3 ligases. J Neurochem 2007;103:2354–2368. [12] Moore DJ. Parkin: a multifaceted ubiquitin ligase. Biochem Soc Trans 2006;34:749–753. [13] Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord 2006;21:1806–1823. [14] Pan T, Kondo S, Le W, Jankovic J. The role of autophagy- lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain 2008;131:1969–1978. [15] Qin ZH, Wang Y, Kegel KB, Kazantsev A, Apostol BL, Thompson LM, et al. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet 2003;12:3231–3244. [16] Ravikumar B, Berger Z, Vacher C, O’Kane CJ, Rubinsztein DC. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 2006;15:1209–1216. This paper was ﬁrst published online on Early Online on 17 February 2012. [17] Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: impli- cations for Parkinson’s disease. Science 2001;293:263–269. [18] Siddiqui A, Mallajosyula JK, Rane A, Andersen JK. Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implica- tions for early intervention on disease progression. Neuro- biol Dis 2010;40:444–448. [19] Sies H. Role of reactive oxygen species in biological pro- cesses. Klin Wochenschr 1991;69:965–968. [20] Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839–840. [21] Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ, et al. Rapamycin activation of 4E-BP pre- vents parkinsonian dopaminergic neuron loss. Nat Neurosci 2009;12:1129–1135. [22] Tanaka A. Parkin-mediated selective mitochondrial auto- phagy, mitophagy: Parkin purges damaged organelles from the vital mitochondrial network. FEBS Lett 2010;584: 1386–1392. [23] Thomas B, Beal MF. Parkinson’s disease. Hum Mol Genet 2007;16(Spec No. 2):R183–R194. [24] Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 1996;264:484–509. [25] Zid BM, Rogers AN, Katewa SD, Vargas MA, Kolipinski MC, Lu TA, et al. 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Dro- sophila. Cell 2009;139:149–160.